<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        REFERENCES<lb/> 
        <bibl><label>1</label>. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health<lb/> Survey (SF-36): I. Conceptual framework and item selection. Med Care.<lb/> 1992;30:473Y483.<lb/> </bibl>
        <bibl><label>2</label>. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item<lb/> Short-Form Health Survey: II. Psychometric and clinical tests of<lb/> validity in measuring physical and mental health constructs. Med Care.<lb/> 1993;31:247Y263.<lb/> </bibl>
        <bibl><label>3</label>. Juniper EF, Guyatt GH. Development and testing of a new measure of<lb/> health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy.<lb/> 1991;21:77Y83.<lb/> </bibl>
        <bibl><label>4</label>. Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a new specific QoL<lb/> questionnaire for patients with rhinitis and asthma. Allergy. 2003;<lb/> 58:289Y294.<lb/> </bibl>
        <bibl><label>5</label>. Chen H, Katz PP, Shiboski S, Blanc PD. Evaluating change in health-<lb/>related quality of life in adult rhinitis: responsiveness of the Rhinosinusitis<lb/> Disability Index. Health Qual Life Outcomes. 2005;3:68.<lb/> </bibl>
        <bibl><label>6</label>. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B.<lb/> Assessment of quality of life in patients with perennial allergic rhinitis<lb/> with the French version of the SF-36 Health Status Questionnaire.<lb/> J Allergy Clin Immunol. 1994;94(2 Pt 1):182Y188.<lb/> </bibl>
        <bibl><label>7</label>. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with<lb/> allergic rhinitis. Ann Allergy Asthma Immunol. 2000;85:338Y348.<lb/> </bibl>
        <bibl><label>8</label>. Baiardini I, Braido F, Cauglia S, Canonica GW. Sleep disturbances in<lb/> allergic rhinitis. Allergy. 2006;61:1259Y1267.<lb/> </bibl>
        <bibl><label>9</label>. Bachert C, Bousquet J, Canonica G, et al. Levocetirizine improves<lb/> quality of life and reduces costs in long-term management of persistent<lb/> allergic rhinitis. J Allergy Clin Immunol. 2004;114:838Y844.<lb/> </bibl>
        <bibl><label>10</label>. Shedden A. Impact of nasal congestion on quality of life and work<lb/> productivity in allergic rhinitis: findings from a large online survey. Treat<lb/> Respir Med. 2005;4:439Y446.<lb/> </bibl>
        <bibl><label>11</label>. Sundberg R, Tore ´n K, Ho ¨glund D, A ˚berg N, Brisman J. Nasal symptoms<lb/> are associated with school performance in adolescents. J Adolesc<lb/> Health. 2007;40:581Y583.<lb/> </bibl>
        <bibl><label>12</label>. Bousquet J, van Cauwenberge P, Khaltaev N, ARIA Workshop Group;<lb/> World Health Organization. Allergic rhinitis and its impact on asthma.<lb/> J Allergy Clin Immunol. 2001;108(suppl):S147YS334.<lb/> </bibl>
        <bibl><label>13</label>. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe:<lb/> findings from a cross-sectional questionnaire survey. Allergy. 2007;<lb/> 62:1057Y1063.<lb/> </bibl>
        <bibl><label>14</label>. Long AA. Findings from a 1000-patient Internet-based survey assessing<lb/> the impact of morning symptoms on individuals with allergic rhinitis.<lb/> Clin Ther. 2007;29:342Y351.<lb/> </bibl>
        <bibl><label>15</label>. Storms WW. Pharmacologic approaches to daytime and nighttime<lb/> symptoms of allergic rhinitis. J Allergy Clin Immunol. 2004;114(suppl 5):<lb/> S146YS153.<lb/> </bibl>
        <bibl><label>16</label>. Young T, Finn L, Kim H, University of Wisconsin Sleep and Respiratory<lb/> Research Group. Nasal obstruction as a risk factor for sleep-disordered<lb/> breathing. J Allergy Clin Immunol. 1997;99:S757YS762.<lb/> </bibl>
        <bibl><label>17</label>. Stuck BA, Czajkowski J, Hagner A-E, et al. Changes in daytime<lb/> sleepiness, quality of life, and objective sleep patterns in seasonal allergic<lb/> rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;<lb/> 113:663Y668.<lb/> </bibl>
        <bibl><label>18</label>. Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves<lb/> quality of life and symptom severity in patients with allergic rhinitis.<lb/> Allergy. 2007;62:1331Y1334.<lb/> </bibl>
        <bibl><label>19</label>. van Cauwenberge P, Juniper EF. STAR study investigating group.<lb/> Comparison of the efficacy, safety and quality of life provided by<lb/> fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo<lb/> administered once daily for the treatment of seasonal allergic rhinitis. Clin<lb/> Exp Allergy. 2000;30:891Y899.<lb/> </bibl>
        <bibl><label>20</label>. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily<lb/> fexofenadine HCl improves quality of life and reduces work and activity<lb/> impairment in patients with seasonal allergic rhinitis. Ann Allergy<lb/> Asthma Immunol. 1999;83:311Y317.<lb/> </bibl>
        <bibl><label>21</label>. Blaiss MS. The role of outcome studies in allergy and clinical<lb/> immunology. Allergy Asthma Proc. 1996;17:355Y358.<lb/> </bibl>
        <bibl><label>22</label>. D&apos;Amato G, Spieksma FThM, Liccardi G, et al. Pollen-related allergy in<lb/> Europe. Allergy. 1998;53:567Y578.<lb/> </bibl>
        <bibl><label>23</label>. Compalati E, Penagos M, Henley K, Canonica GW. Allergy prevalence<lb/> survey by the World Allergy Organization. Allergy Clin Immunol Int.<lb/> 2007;19:82Y90.</bibl>
        </listBibl>
    </text>
</tei>

